Metformina + Vildagliptina Ciclum

Metformin Hydrochloride and Vildagliptin, the active ingredient in Metformina + Vildagliptina Ciclum, is a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients. It is marketed in the European Union and meets EU pharmacopoeial specifications.\n\nGNH India supplies Metformina + Vildagliptina Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Metformina + Vildagliptina Ciclum combines metformin and vildagliptin to improve glycemic control in type 2 diabetes.\n- Type 2 diabetes mellitus: improves fasting and postprandial glucose levels.\n- Adjunct to diet and exercise: enhances overall glycemic management when lifestyle measures are insufficient.\n- Combination therapy: used when metformin alone does not achieve target glycemic control.

The combination may be associated with various adverse reactions, which are categorized by frequency.\n\nCommon Side Effects:\n- Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.\n- Headache: mild to moderate intensity.\n- Dizziness: transient episodes, especially on initiation.\n- Hypoglycemia: when used with other glucose‑lowering agents such as sulfonylureas or insulin.\n\nSerious or Rare Side Effects:\n- Lactic acidosis: rare but potentially fatal metabolic disturbance.\n- Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.\n- Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain.

When prescribing Metformina + Vildagliptina Ciclum, consider the following precautions.\n- Renal function: assess creatinine clearance before initiating and monitor periodically.\n- Hepatic disease: avoid in patients with significant liver impairment due to lactic acidosis risk.\n- Heart failure: use with caution in unstable congestive heart failure.\n- Concomitant sulfonylureas or insulin: monitor for hypoglycemia and adjust dose as needed.\n- Pregnancy and lactation: safety not established; use only if potential benefit justifies risk.\n- Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Metformina + Vildagliptina Ciclum may interact with several medicines; interactions are grouped by clinical significance.\n\nMajor Interactions (Avoid):\n- Iodinated contrast agents: may precipitate acute renal failure; discontinue metformin before and after exposure.\n- Strong CYP2C9 inhibitors (e.g., fluconazole): can increase vildagliptin plasma levels, raising risk of adverse effects.\n\nModerate Interactions (Monitor Closely):\n- Sulfonylureas or insulin: additive glucose‑lowering effect, increasing hypoglycemia risk.\n- Diuretics (thiazides): may elevate plasma metformin concentrations.\n- Cimetidine: can reduce renal clearance of metformin, necessitating dose adjustment.